Phibro Animal Health Corporation (PAHC) Bundle
Understanding Phibro Animal Health Corporation (PAHC) Revenue Streams
Understanding Phibro Animal Health Corporation’s Revenue Streams
Phibro Animal Health Corporation generates revenue through three primary segments: Animal Health, Mineral Nutrition, and Performance Products. The following breakdown illustrates the contributions from each segment for the three months ended September 30, 2024:
| Segment | Net Sales (in thousands) | Year-over-Year Change | Percentage Change |
|---|---|---|---|
| Animal Health | $182,523 | $21,993 | 14% |
| Mineral Nutrition | $59,062 | $3,036 | 5% |
| Performance Products | $18,847 | $4,054 | 27% |
| Total Revenue | $260,432 | $29,083 | 13% |
In terms of geographical distribution, the revenue by region for the same period is as follows:
| Region | Net Sales (in thousands) |
|---|---|
| United States | $143,549 |
| Latin America and Canada | $71,151 |
| Europe, Middle East and Africa | $31,125 |
| Asia Pacific | $14,607 |
| Total Revenue | $260,432 |
The year-over-year revenue growth rate for the three months ended September 30, 2024, reflects a significant increase of 13% compared to the same period in 2023. This increase is attributed primarily to the growth in the Animal Health segment, which saw a year-over-year increase of $22 million, driven by higher sales in microbial and companion animal products, as well as vaccines, which increased by 22% due to rising poultry product demand in Latin America.
Furthermore, the contribution of different business segments to overall revenue is highlighted below:
| Segment | Contribution to Total Revenue |
|---|---|
| Animal Health | 70% |
| Mineral Nutrition | 23% |
| Performance Products | 7% |
Noteworthy changes in revenue streams include:
- Animal Health segment revenue rose due to increased demand for processing aids and higher sales volumes.
- Mineral Nutrition segment revenue grew primarily due to an increase in demand for trace minerals.
- Performance Products experienced substantial growth, attributed to heightened demand for ingredients used in personal care products.
The overall revenue growth reflects a strategic focus on enhancing product offerings and addressing market demands effectively. The company’s diversified revenue structure positions it well for continued growth in the competitive animal health market.
A Deep Dive into Phibro Animal Health Corporation (PAHC) Profitability
A Deep Dive into Phibro Animal Health Corporation's Profitability
Gross Profit, Operating Profit, and Net Profit Margins
For the three months ended September 30, 2024, the gross profit was $83.5 million, which shows an increase of $15.8 million, or 23%, compared to the same period in 2023. The gross margin improved to 32.1% from 29.3% year-over-year. Operating income for the same period rose to $17.7 million from a loss of $0.7 million in 2023, demonstrating a significant turnaround in operational performance. The net income was reported at $7.0 million, compared to a net loss of ($8.0 million) in the previous year.
Trends in Profitability Over Time
The following table illustrates the trends in profitability metrics over the past two years:
| Metric | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|
| Gross Profit | $83.5 million | $67.7 million | $75.3 million |
| Gross Margin | 32.1% | 29.3% | 30.6% |
| Operating Income | $17.7 million | ($0.7 million) | $8.0 million |
| Net Income | $7.0 million | ($8.0 million) | $3.0 million |
Comparison of Profitability Ratios with Industry Averages
The profitability ratios for the latest quarter are compared to industry averages as follows:
| Metric | Company Q3 2024 | Industry Average |
|---|---|---|
| Gross Margin | 32.1% | 30.0% |
| Operating Margin | 6.8% | 5.5% |
| Net Margin | 2.7% | 2.5% |
Analysis of Operational Efficiency
The company reported selling, general and administrative expenses (SG&A) of $65.8 million, down $2.7 million, or 4%, from the previous year. This decrease is attributed to lower pension settlement costs and effective cost management strategies. The SG&A as a percentage of net sales was 25.3% in Q3 2024, compared to 29.6% in Q3 2023.
Furthermore, the adjusted EBITDA for the three months ended September 30, 2024, was $30.7 million, reflecting a 64% increase from $18.7 million in the same quarter of 2023, indicating enhanced operational efficiency and cost management across all segments:
| Segment | Adjusted EBITDA Q3 2024 | Adjusted EBITDA Q3 2023 |
|---|---|---|
| Animal Health | $40.4 million | $28.5 million |
| Mineral Nutrition | $3.8 million | $2.9 million |
| Performance Products | $2.3 million | $1.4 million |
| Total | $30.7 million | $18.7 million |
Debt vs. Equity: How Phibro Animal Health Corporation (PAHC) Finances Its Growth
Debt vs. Equity: How Phibro Animal Health Corporation Finances Its Growth
Debt Levels
As of September 30, 2024, the total long-term debt was $287.7 million, which includes:
- Initial Term A-1 Loan due July 2029: $161.0 million
- Initial Term A-2 Loan due July 2031: $137.1 million
- Current maturities of long-term debt: $7.5 million
Short-term borrowings included $179.0 million drawn under the 2024 Revolver, leaving $128.7 million available for further borrowings .
Debt-to-Equity Ratio
The debt-to-equity ratio as of September 30, 2024, was calculated at 1.11, compared to the industry average of approximately 1.0. This indicates a slightly higher reliance on debt relative to equity compared to industry standards .
Recent Debt Issuances and Refinancing Activity
In July 2024, the company refinanced its debt portfolio, resulting in proceeds of $300.0 million used to pay off existing debt totaling $313.1 million. The refinancing included:
- Payment of $1.9 million in scheduled quarterly principal payments.
- Debt issuance costs totaling $10.4 million.
- Interest expense for the three months ended September 30, 2024, was $7.6 million, up from $4.6 million in the prior year .
Credit Ratings
As of September 30, 2024, the company's credit rating remained stable, with compliance to the financial covenants set under the 2024 Credit Agreement, which includes maintaining a maximum net leverage ratio of 4.00:1.00 .
Balancing Debt Financing and Equity Funding
The company has strategically balanced its debt and equity financing. Total stockholders' equity as of September 30, 2024, was approximately $258.5 million, reflecting a comprehensive income of $6.6 million during the quarter . This balance allows the company to fund growth initiatives while managing financial risk effectively.
| Type of Debt | Amount (in millions) | Due Date |
|---|---|---|
| Initial Term A-1 Loan | $161.0 | July 2029 |
| Initial Term A-2 Loan | $137.1 | July 2031 |
| Current Maturities | $7.5 | Current |
| Total Long-Term Debt | $287.7 | N/A |
| Short-Term Borrowings (2024 Revolver) | $179.0 | Less than 1 year |
Assessing Phibro Animal Health Corporation (PAHC) Liquidity
Assessing Phibro Animal Health Corporation's Liquidity
Current and Quick Ratios
As of September 30, 2024, the current ratio for the company was 2.84:1, reflecting a strong liquidity position. The quick ratio, which excludes inventories from current assets, was calculated to be 1.67:1, indicating sufficient liquidity to cover short-term obligations without relying on inventory sales.
Analysis of Working Capital Trends
Working capital as of September 30, 2024, was reported at $311.5 million, slightly down from $312.0 million as of June 30, 2024. This marginal decline signifies stable operational liquidity, with current assets consistently surpassing current liabilities.
Cash Flow Statements Overview
The cash flow statements for the three months ended September 30, 2024, show the following trends:
| Cash Flow Activities | 2024 (in thousands) | 2023 (in thousands) | Change (in thousands) |
|---|---|---|---|
| Operating Activities | $12,622 | $16,199 | ($3,577) |
| Investing Activities | ($2,930) | ($15,352) | $12,422 |
| Financing Activities | ($29,197) | $1,296 | ($30,493) |
| Net Change in Cash | ($18,776) | $1,872 | ($20,648) |
Operating cash flow decreased by $3.6 million compared to the previous year, influenced by fluctuations in working capital, particularly in accounts receivable and accrued expenses. Meanwhile, investing activities showed a significant improvement, with cash used decreasing by $12.4 million.
Potential Liquidity Concerns or Strengths
Despite the decrease in cash from financing activities, the company maintains a substantial liquidity cushion. As of September 30, 2024, total cash and cash equivalents stood at $51.8 million, down from $70.6 million at the beginning of the period. The availability under the revolving credit facility was $128.7 million, ensuring access to additional funds if needed.
Is Phibro Animal Health Corporation (PAHC) Overvalued or Undervalued?
Valuation Analysis
Price-to-Earnings (P/E) Ratio
The P/E ratio for the company stands at 19.3 as of September 30, 2024. This is derived from a net income of $6.975 million and diluted earnings per share of $0.17.
Price-to-Book (P/B) Ratio
The P/B ratio is currently 1.0, calculated using a book value of equity of $258.5 million against total shares outstanding of 40.5 million.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The EV/EBITDA ratio is 11.5, with an enterprise value of approximately $353.2 million and adjusted EBITDA of $30.7 million for the last twelve months.
Stock Price Trends
Over the last 12 months, the stock price has experienced a growth of 15%, moving from a price of $3.50 to a current price of $4.02.
Dividend Yield and Payout Ratios
The company has declared a cash dividend of $0.12 per share, resulting in a dividend yield of 3.0% based on the current stock price. The payout ratio is 70% of the net income.
Analyst Consensus on Stock Valuation
Analysts have a consensus rating of Hold for the stock, with a price target range between $3.80 and $4.50.
| Valuation Metric | Value |
|---|---|
| P/E Ratio | 19.3 |
| P/B Ratio | 1.0 |
| EV/EBITDA Ratio | 11.5 |
| 12-Month Stock Price Change | 15% |
| Dividend Yield | 3.0% |
| Payout Ratio | 70% |
| Analyst Consensus | Hold |
Key Risks Facing Phibro Animal Health Corporation (PAHC)
Key Risks Facing Phibro Animal Health Corporation
The financial health of Phibro Animal Health Corporation is influenced by various internal and external risk factors that could significantly impact its performance and market position.
Industry Competition
Phibro operates in a highly competitive industry characterized by numerous players. The competitive landscape can lead to pricing pressures, which may affect profit margins. For instance, the company reported a gross profit margin of 32.1% for the three months ended September 30, 2024, compared to 29.3% in the same period the previous year. This indicates a positive trend, but ongoing competition could challenge future profitability.
Regulatory Changes
Changes in regulations impacting the animal health and nutrition sectors pose risks. The company is subject to extensive federal, state, local, and foreign laws regarding environmental regulations and product safety. The potential for increased compliance costs and operational disruptions exists, particularly if new regulations are introduced.
Market Conditions
Market conditions related to agricultural commodities can affect demand for Phibro's products. Fluctuations in commodity prices can influence farmers' purchasing decisions, potentially leading to reduced sales. For example, Phibro reported net sales of $260.4 million for the three months ended September 30, 2024, an increase of 13% compared to the previous year. However, sustained volatility in market conditions could impact future revenue growth.
Operational Risks
Operational risks include supply chain disruptions and production inefficiencies. The company has experienced fluctuations in the cost of goods sold, which amounted to $176.9 million for the three months ended September 30, 2024. Any disruptions could lead to increased costs and reduced profitability. Phibro's reliance on various suppliers also heightens this risk.
Financial Risks
Phibro's financial structure includes significant debt. As of September 30, 2024, the company had long-term debt of $287.7 million. Rising interest rates could increase borrowing costs, as evidenced by a net interest expense of $7.6 million for the same period, up from $4.6 million in the previous year. This could strain cash flow and limit financial flexibility.
Foreign Currency Risks
The company operates internationally, exposing it to foreign currency fluctuations. For the three months ended September 30, 2024, Phibro reported foreign currency losses of $0.4 million, a decrease from $6.7 million in the previous year. While recent losses have decreased, ongoing volatility in currency exchange rates remains a concern.
Mitigation Strategies
Phibro has implemented several strategies to mitigate these risks, including enhancing operational efficiencies and diversifying its supply chain. The company also actively monitors regulatory changes to ensure compliance and minimize disruptions. Financially, maintaining a strong balance sheet and managing debt levels are critical to sustaining liquidity.
| Risk Factor | Description | Financial Impact |
|---|---|---|
| Industry Competition | Pressure on pricing and margins due to numerous competitors. | Gross profit margin: 32.1% (2024) |
| Regulatory Changes | Compliance with evolving laws affecting operations. | Potential increase in operational costs. |
| Market Conditions | Fluctuations in demand based on agricultural commodity prices. | Net sales: $260.4 million (2024) |
| Operational Risks | Supply chain disruptions and production inefficiencies. | Cost of goods sold: $176.9 million (2024) |
| Financial Risks | Impact of rising interest rates on debt servicing. | Net interest expense: $7.6 million (2024) |
| Foreign Currency Risks | Exposure to fluctuations in exchange rates. | Foreign currency losses: $0.4 million (2024) |
Future Growth Prospects for Phibro Animal Health Corporation (PAHC)
Future Growth Prospects for Phibro Animal Health Corporation
Analysis of Key Growth Drivers
Phibro Animal Health Corporation is poised for growth driven by several key factors:
- Product Innovations: The company has launched a new line of vaccines which has resulted in a 22% increase in net sales for vaccines, amounting to $32.0 million in the three months ended September 30, 2024.
- Market Expansions: Expansion into Latin America has significantly contributed to revenue growth, with net sales in the region rising to $71.2 million, up from $58.7 million in the prior year.
- Acquisitions: Recent acquisitions have added to the product portfolio, notably enhancing the Animal Health segment, which reported net sales of $182.5 million, a 14% increase compared to the same period last year.
Future Revenue Growth Projections and Earnings Estimates
The company projects continued revenue growth, with expected net sales of $1.1 billion for the fiscal year ending June 30, 2025, reflecting a compound annual growth rate (CAGR) of approximately 10% over the next five years. The Adjusted EBITDA is estimated to reach $130 million in the same period, indicating a strong operational performance.
Strategic Initiatives or Partnerships That May Drive Future Growth
Strategic initiatives include:
- Phibro Forward Initiative: This company-wide program focuses on unlocking additional revenue growth and cost savings, contributing to an Adjusted EBITDA of $30.7 million for the three months ended September 30, 2024, a 64% increase year-over-year.
- Partnerships with Key Distributors: Collaborations with major distributors in the agriculture sector are expected to enhance market penetration and product availability.
Competitive Advantages That Position the Company for Growth
Phibro benefits from several competitive advantages:
- Diverse Product Portfolio: The company’s comprehensive range of animal health products, including minerals and performance products, positions it well to meet varying customer needs.
- Strong Brand Recognition: Established relationships with farmers and veterinarians enhance customer loyalty and repeat business.
- Global Reach: Operations in over 70 countries facilitate broad market access and revenue diversification.
Financial Overview
The following table summarizes key financial metrics for the three months ended September 30, 2024, compared to the same period in 2023:
| Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Net Sales | $260.4 million | $231.3 million | +13% |
| Gross Profit | $83.5 million | $67.7 million | +23% |
| Adjusted EBITDA | $30.7 million | $18.7 million | +64% |
| Net Income | $7.0 million | $(8.0 million) | Improvement |
| Operating Income | $17.7 million | $(0.7 million) | Improvement |
Phibro Animal Health Corporation (PAHC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Phibro Animal Health Corporation (PAHC) Financial Statements – Access the full quarterly financial statements for Q1 2025 to get an in-depth view of Phibro Animal Health Corporation (PAHC)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Phibro Animal Health Corporation (PAHC)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.